Shark Tank India Judge Namita Thapar's Emcure Pharma Set To Launch IPO Soon, Her Net Worth Is Rs 600 Crore
Namita Thapar, who is the Executive Director (India Business) of Emcure Pharmaceuticals, had said earlier this month at the ET NOW Global Business Summit 2024 that the company plans to launch its IPO within three months. The company is reportedly targeting a valuation of about $3 billion.
At a time when Shark Tank India judge Ritesh Agarwal¡¯s OYO is inching closer towards launching its much awaited IPO, it seems that another shark¡¯s company is planning to go public.
Namita Thapar's Emcure Pharma Set To Launch IPO Soon
Namita Thapar Shark tank/Twitter
Namita Thapar, who is the Executive Director (India Business) of Emcure Pharmaceuticals, had said earlier this month at the ET NOW Global Business Summit 2024 that the company plans to launch its IPO within three months. The company is reportedly targeting a valuation of about $3 billion.
At the event, Shark Tank India judge Namita Thapar had said, ¡°So my father is a first-gen entrepreneur, and we run Emcure Pharmaceuticals. We're going to go public in 3 months so watch out for that big IPO."
She added that Emcure Pharma will soon introduce a direct-to-consumer (D2C) product and that, although up until now, only doctors have been the company's customers, regular people will now also purchase the company's goods.
To raise money through IPO, Emcure Pharmaceuticals, backed by Bain Capital, submitted new preliminary documents to SEBI, India's capital markets regulator, earlier in December.
According to the draft red herring prospectus filed in December, the IPO consists of an Offer of Sale (OFS) of 1.36 crore equity shares by promoters and current shareholders, along with a new issuance of equity shares valued at Rs 800 crore.
emcure pharma ipo/shutterstock
Promoter Satish Mehta and investor BC Investments IV Ltd., a subsidiary of US-based private equity giant Bain Capital, are among those selling shares in the OFS, as per ET report. At the moment, Bain Capital Investments owns a 13.09% stake in the business, while Satish Mehta owns 41.92%.
Big Banks Pitch In To Manage The IPO Preparation
The IPO proceeds will be applied to general corporate purposes and debt repayment. Emcure Pharma's IPO's book-running lead managers are Kotak Mahindra Capital Company, Jefferies India, Axis Capital, and JP Morgan India. It is suggested that the equity shares be listed on the NSE and BSE.
emcure pharma ipo/emcure pharma
Also Read:
Is Emcure Pharma A Profitable Company?
Yes, Namita Thapar¡¯s Emcure Pharma is currently a profitable company, with Rs 160 crore (Rs 1600 million) profit in FY23, and a revenue of Rs 3107 crore. Emcure pharma is among the very few companies among shark tank india judges which arre profitable, given that most of them are under losses. Click here to know which sharks¡¯ companies are profitable/those that are incurring losses.
